Fig. 3
Domatinostat synergizes with PD-L1 blockade to prolong survival. CT26 tumor model as in Fig. 1; animals were treated with 20 mg/kg domatinostat twice daily, 10 mg/kg anti-PD-L1 antibody twice a week or the combination of both and were compared with vehicle-treated animals (n = 20 per group). a, Tumor volumes (mean ± SD) over time. b, Kaplan-Meier event-free survival plots. An event was defined as a tumor volume of 1500 mm3. P-values: a, Kruskal-Wallis test (d19); Dunn’s multiple comparison to vehicle. b, Log-rank (Mantel-Cox) test, comparison to vehicle. *, P < 0.05; ****, P < 0.0001; ns, not significant